The global market for products in cell therapy and tissue engineering has ballooned from a nascent market only a few years ago to big business, currently pushing almost $7 billion annually.
Source: Report #S520
There are many well established medtech market competitors active in cell therapy and tissue engineering, including Medtronic, Baxter, Zimmer, Stryker, and Genzyme, but there are also a slew of of other participants with products on the market and in clinical trials. As is evident from the above, the predominant applications are in orthopedics, skin, cardiology and cancer, but aggressive growth is taking place in the other, emerging applications.
The market is developing through the progressive adoption of cell therapy and tissue engineering approaches to disease management in clinical applications globally. A predominance of the market is in the U.S. and Europe, but as the market evolves, the share of revenues from other markets is increasing.
See Report #S520 (publishing February 2010), "Worldwide Cell Therapy & Tissue Engineering Markets, 20098-2018."
Trackbacks & Pingbacks 2
[...] Big Business in Cell Therapy & Tissue Engineering [...]
[...] Big Business in Cell Therapy & Tissue Engineering [...]
Post a Comment